By: Elías El Hage It's fascinating to see how the European press and international news agencies have fallen into a collective trance, dubbing Lenacapvir the "six-monthly vaccine." A semantic error bordering on irresponsibility. While in the comfortable health centers of Madrid or Berlin this advance is celebrated as the end of the era of […]
Lenacapvir: The fetish of the "vaccine" and the slap of inequality Read More »
The director of UNAIDS for Latin America and the Caribbean, Luisa Cabal, called on Monday in Panama for greater efforts in HIV/AIDS prevention in the region, where new infections have increased by 5% since 2010.
UNAIDS calls on Latin America to increase efforts in HIV/AIDS prevention Read More »
Pérez C, Guillén A, Caraballo S, Silva E, Gonzalez J, Guzman M, Comegna M. Materials and methods: Observational, retrospective and descriptive study that included patients diagnosed with HIV who died at the Vargas Hospital of Caracas (HVC) during the year 2018. The data were processed in the IBM SPSS Statistics® version 20 program and
Mortality in hospitalized patients diagnosed with Human Immunodeficiency Virus Infection Read More »
By EFE in Washington, July 29, 2019 - A team led by Steven Forsythe of the Avenir Health organization in the US evaluated the results between 1995 and 2015, according to an article published yesterday in the journal Health Affairs. Antiretroviral therapies for the human immunodeficiency virus (HIV) prevented 9.5 million deaths worldwide between 1995 and 2015.
Antiretroviral therapy prevented 9.5 million HIV deaths. Read More »
No one knew what killed Robert Rayford. The African American boy was only 15 years old when he showed up at St. Louis City Hospital in late 1968, but the medical team was baffled. An unexplained swelling in Rayford's genitals soon spread throughout his body. Chlamydia bacteria, usually
Fifty years of HIV: How close are we to a cure? Read More »
Avirulins may provide a valuable chemical basis for the development of the next generation of HIV-1 prophylactic drugs for women, according to the results of a study presented at the American Society of Microbiology (ASM) Microbe 2019, held June 20–24, 2019, in San Francisco, California. https://www.infectiousdiseaseadvisor.com/author/natashadyal/ Although it
The new HIV-1 inhibitor shows promise for future HIV treatment in women. Read More »
By: Kenyon Farrow https://www.thebodypro.com/article/long-acting-hiv-meds-are-acceptable-to-many-people-but-differences-exist-among-groups Now that long-acting antiretroviral therapy (LA-ART) is almost a reality, is it something people with HIV will prefer over once-a-day pills? A study presented during a poster session at the International Conference on HIV Treatment and Prevention sought to find out
By: Carole Leach-Lemens http://www.aidsmap.com/page/3536366/ In the first five years of life, the neurological development of HIV-exposed but uninfected infants exposed to maternal antiretrovirals before and after birth and during breastfeeding is comparable to that of uninfected infants without HIV from similar socioeconomic backgrounds, a study
Antiretroviral drugs do not cause neurodevelopmental harm in uninfected infants. Read More »
By: Manuel Ansede – https://elpais.com/autor/manuel_ansede_vazquez/a/ Denis Rebrikov plans a similar experiment to the one carried out in China, despite international rejection. Just over six months after the birth in China of the first two genetically modified babies, a Russian scientist has announced that he intends to carry out a similar experiment, despite the unanimous rejection of the international community.
A Russian scientist aims to create more genetically modified babies. Read More »
French doctor leads the largest trial on the use of PrEP, pre-exposure prophylaxis in real life By: EMILIO DE BENITO – Elpais.com The IPERGAY study (2015) confirmed the evidence that a pill taken before unprotected sex prevented HIV infection (pre-exposure prophylaxis or PrEP). And the
“The HIV pill is a human rights issue” Read More »
